文章：

来那度胺联合地塞米松，加或不加克拉霉素，用于不适合自体移植的多发性骨髓瘤患者：一项随机试验

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

原文发布日期：2021-05-26

DOI: 10.1038/s41408-021-00494-4

类型: Article

开放获取: 是

英文摘要：

Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial changes (MECs), eye examination findings with/without symptoms), were common, consistent with reports from other antibody–drug conjugates. Given the novel nature of corneal events in RRMM management, guidelines are required for their prompt identification and appropriate management. Eye examination findings from DREAMM-2 and insights from hematology/oncology investigators and ophthalmologists, including corneal specialists, were collated and used to develop corneal event management guidelines. The following recommendations were formulated: close collaboration among hematologist/oncologists and eye care professionals is needed, in part, to provide optimal care in relation to the belamaf benefit–risk profile. Patients receiving belamaf should undergo eye examinations before and during every treatment cycle and promptly upon worsening of symptoms. Severity of corneal events should be determined based on corneal examination findings and changes in best-corrected visual acuity. Treatment decisions, including dose modifications, should be based on the most severe finding present. These guidelines are recommended for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf. Video Summary
 

摘要翻译： 

Belantamab mafodotin（belamaf）在DREAMM-2研究（NCT03525678）中，对经过深度治疗的复发或难治性多发性骨髓瘤患者显示出深度且持久的疗效。角膜事件，尤其是角膜病变（包括浅层点状角膜病变和/或微囊样上皮改变，伴有或不伴有症状的眼科检查发现）较为常见，这与其他抗体药物偶联物的报道一致。鉴于角膜事件在多发性骨髓瘤治疗中的新颖性，需要制定指南以促进其及时识别和适当管理。研究人员整理了DREAMM-2中的眼科检查结果，并汇集了血液肿瘤学专家和眼科医生（包括角膜专家）的意见，制定了角膜事件管理指南。建议如下：血液肿瘤科医生与眼科专业人员需密切合作，部分目的是根据belamaf的获益-风险特征提供最佳治疗。接受belamaf治疗的患者应在每个治疗周期前和治疗期间进行眼科检查，并在症状加重时立即检查。角膜事件的严重程度应根据角膜检查结果和最佳矫正视力的变化来确定。治疗决策（包括剂量调整）应基于最严重的检查结果。推荐使用这些指南来评估和管理与belamaf相关的眼部事件，以帮助减轻眼部风险，使患者能够继续从belamaf治疗中获得临床获益。视频摘要。

原文链接：

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)